Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Affimed stock logo
AFMD
Affimed
$0.18
-34.9%
$0.30
$0.07
$5.84
$2.92M2.074.63 million shs22.99 million shs
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
$2.09
-2.8%
$1.68
$0.73
$3.90
$136.08M0.7412,959 shs206,406 shs
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$0.39
$0.19
$28.00
$906K2.19462,687 shs2.25 million shs
OASM
Oasmia Pharmaceutical AB (publ)
$0.02
$1.46
$0.94
$5.70
$1.50M0.9698,414 shsN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$3.14
-0.9%
$2.62
$1.12
$3.20
$145.76M0.55883,233 shs1.63 million shs
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Affimed stock logo
AFMD
Affimed
0.00%0.00%0.00%-70.96%-96.28%
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-2.79%-5.86%+58.33%+53.68%-4.57%
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00%0.00%0.00%0.00%0.00%
OASM
Oasmia Pharmaceutical AB (publ)
0.00%0.00%0.00%0.00%-59.92%
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-0.95%+36.52%+21.71%+121.13%+125.90%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Affimed stock logo
AFMD
Affimed
2.932 of 5 stars
4.00.00.04.30.60.01.3
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
1.639 of 5 stars
3.50.00.00.02.81.70.0
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/AN/AN/AN/A
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Affimed stock logo
AFMD
Affimed
2.00
Hold$3.621,895.87% Upside
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
3.00
Buy$6.00187.08% Upside
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
0.00
N/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
0.00
N/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
3.00
BuyN/AN/A

Current Analyst Ratings Breakdown

Latest GALT, AFMD, NEPT, THTX, and OASM Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/3/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
6/17/2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Initiated CoverageBuy$6.00
5/14/2025
Affimed stock logo
AFMD
Affimed
Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/14/2025
Affimed stock logo
AFMD
Affimed
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeBuy ➝ Neutral
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partnrs
Subscribe to MarketBeat All Access for the recommendation accuracy rating
DowngradeStrong-Buy ➝ Hold
5/13/2025
Affimed stock logo
AFMD
Affimed
Wells Fargo & Company
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOverweight ➝ Equal Weight$11.00 ➝ $0.10
5/13/2025
Affimed stock logo
AFMD
Affimed
Leerink Partners
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform ➝ Market Perform$5.00 ➝ $0.39
4/11/2025
Theratechnologies Inc. stock logo
THTX
Theratechnologies
Jones Trading
Subscribe to MarketBeat All Access for the recommendation accuracy rating
UpgradeHold ➝ Strong-Buy
(Data available from 7/9/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Affimed stock logo
AFMD
Affimed
$877K3.33N/AN/A$4.19 per share0.04
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/A($1.68) per shareN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
$52.62M0.00N/AN/A($91.90) per share0.00
OASM
Oasmia Pharmaceutical AB (publ)
$220K6.82N/AN/A$0.63 per share0.03
Theratechnologies Inc. stock logo
THTX
Theratechnologies
$85.87M1.68N/AN/A($0.55) per share-5.71
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Affimed stock logo
AFMD
Affimed
-$114.66MN/A0.00N/AN/A-7,836.26%-193.84%-107.24%9/1/2025 (Estimated)
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$47.05M-$0.72N/AN/AN/AN/AN/A-216.05%8/12/2025 (Estimated)
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
-$60.46M-$106.72N/AN/AN/A-128.13%N/A-141.94%N/A
OASM
Oasmia Pharmaceutical AB (publ)
-$18.95MN/A0.00N/A-8,633.64%-43.94%-28.92%N/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
-$8.31M-$0.08N/A44.86N/A-4.18%N/A-0.37%7/9/2025 (Estimated)

Latest GALT, AFMD, NEPT, THTX, and OASM Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
5/15/2025Q1 2025
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
-$0.20-$0.15+$0.05-$0.15N/AN/A
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Affimed stock logo
AFMD
Affimed
N/AN/AN/AN/AN/A
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/AN/AN/AN/AN/A
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/AN/AN/AN/AN/A
OASM
Oasmia Pharmaceutical AB (publ)
N/AN/AN/AN/AN/A
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Affimed stock logo
AFMD
Affimed
0.13
1.93
1.93
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
N/A
0.08
0.08
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
N/A
0.23
0.10
OASM
Oasmia Pharmaceutical AB (publ)
N/A
0.80
0.73
Theratechnologies Inc. stock logo
THTX
Theratechnologies
N/A
1.08
0.88
CompanyEmployeesShares OutstandingFree FloatOptionable
Affimed stock logo
AFMD
Affimed
20016.10 million15.49 millionOptionable
Galectin Therapeutics Inc. stock logo
GALT
Galectin Therapeutics
963.29 million31.58 millionOptionable
Neptune Wellness Solutions Inc stock logo
NEPT
Neptune Wellness Solutions
584.53 million4.30 millionNot Optionable
OASM
Oasmia Pharmaceutical AB (publ)
5774.97 millionN/ANot Optionable
Theratechnologies Inc. stock logo
THTX
Theratechnologies
14045.98 millionN/AOptionable

Recent News About These Companies

Future Pak to buy Theratechnologies for $254 million
Theratechnologies Inc. (THTX) - Yahoo Finance
Theratechnologies to further evaluate potential sale of the company
Theratechnologies Provides Update on Sale Process
Theratechnologies Provides Update on Sale Process

New MarketBeat Followers Over Time

Media Sentiment Over Time

Affimed stock logo

Affimed NASDAQ:AFMD

$0.18 -0.10 (-34.95%)
As of 05/19/2025

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Galectin Therapeutics stock logo

Galectin Therapeutics NASDAQ:GALT

$2.09 -0.06 (-2.79%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$2.12 +0.04 (+1.67%)
As of 07/8/2025 07:56 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the research and development of therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02) galectin-3 inhibitor, that is in Phase 2b/3 clinical trial, to prevent esophageal varices in patient with non-alcoholic steatohepatitis (NASH) cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and head and neck squamous cell carcinoma. The company, through its Galectin Sciences, LLC, which is a collaborative joint venture co-owned by SBH Sciences, Inc., to research and develop small organic molecule inhibitors of galectin-3 for oral administration. The company was formerly known as Pro-Pharmaceuticals, Inc. and changed its name to Galectin Therapeutics, Inc. in May 2011. Galectin Therapeutics Inc. was founded in 2000 and is based in Norcross, Georgia.

Neptune Wellness Solutions stock logo

Neptune Wellness Solutions NASDAQ:NEPT

Neptune Wellness Solutions Inc., a health and wellness products company, specializes in the extraction, purification and formulation of cannabis products, as well as other specialty ingredients, such as MaxSimil, a patented ingredient that enhances the absorption of lipid-based nutraceuticals, and various other marine and seed oils. Its custom formulations are available in various delivery forms, such as softgels, liquid solutions, nutritional emulsions, and chewables. Neptune Wellness Solutions Inc. was founded in 1998 and is headquartered in Laval, Canada.

Oasmia Pharmaceutical AB (publ) NASDAQ:OASM

Oasmia Pharmaceutical AB engages in the research and development of drugs. It formulates pharmaceutical products for ovarian and breast cancer for humans and cancer for animals. The company was founded by Julian Aleksov and Bo Cederstrand on April 15, 1988 and is headquartered in Uppsala, Sweden.

Theratechnologies stock logo

Theratechnologies NASDAQ:THTX

$3.14 -0.03 (-0.95%)
Closing price 07/8/2025 04:00 PM Eastern
Extended Trading
$3.14 +0.00 (+0.16%)
As of 05:33 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Theratechnologies Inc., a biopharmaceutical company, focuses on the development and commercialization of various therapies to address the unmet medical needs in the United States, Canada, and Europe. The company offers EGRIFTA SV for the reduction of excess abdominal fat in human immunodeficiency virus (HIV)-infected patients with lipodystrophy; and Trogarzo for the treatment of HIV-1 infection in heavily treatment-experienced adults with multidrug-resistant HIV-1 infection failing their current antiretroviral regimen. Its pipeline products include F8 Formulation that is in Phase 2b/3 clinical trials for studying tesamorelin for the treatment of nonalcoholic steatohepatitis; multi -dose pen injector for the administration of tesamorelin; SORT1+ Technology Platform for the development of proprietary peptides for cancer drug development targeting SORT1 receptors; Sudocetaxel Zendusortide, which is in Phase 1 Clinical Trial for various solid tumor types, including HR+ breast, triple negative breast, ovarian, endometrial, melanoma, thyroid, small cell lung, and prostate cancers. The company was incorporated in 1993 and is headquartered in Montreal, Canada.